A Retrospective Observational Study in the Expanded Access Program of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer (BEACON EAP Follow-up Study )
Not Applicable
- Conditions
- BRAF V600E-mutant metastatic colorectal cancerD015179
- Registration Number
- JPRN-jRCT1031220225
- Lead Sponsor
- Daisuke Kotani
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 57
Inclusion Criteria
Patients who received encorafenib, binimetinib, and cetuximab in the BEACON CRC Expanded Access Program from February 2020 to January 2021 and who participated in the study until the end of the study.
Exclusion Criteria
none
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method